Pharmacological management of sickle cell disease

P and T

Volumn 33, Issue 4, 2008, Pages 238-243

  Ndefo, Uche Anadu ^a,b   Maxwell, Angie Eaton ^a,b   Nguyen, Huong ^a   Chiobi, Tochukwu L ^a  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b HARRIS COUNTY HOSPITAL DISTRICT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTISICKLING AGENT; ARGININE; CODEINE; DEFERASIROX; DEFEROXAMINE MESYLATE; FENTANYL; FOLIC ACID; GLUTAMINE; HEMOXIN; HYDROCODONE; HYDROMORPHONE; HYDROXYUREA; IBUPROFEN; KETOROLAC; KETOROLAC TROMETAMOL; MAGNESIUM; MORPHINE; MORPHINE SULFATE; NITRIC OXIDE; PARACETAMOL; PENICILLIN V POTASSIUM; PETHIDINE; PLACEBO; PNEUMOCOCCUS VACCINE; PROSTACYCLIN; PSEUDOEPHEDRINE; SILDENAFIL; TERBUTALINE; TRAMADOL;

BACTERIAL ARTHRITIS; BONE MARROW APLASIA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG SAFETY; EXCHANGE BLOOD TRANSFUSION; FEVER; HUMAN; INFECTION; MEGALOBLASTIC ANEMIA; MENINGITIS; OSTEOMYELITIS; PAIN; PRIAPISM; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SEPSIS; SICKLE CELL ANEMIA; STREPTOCOCCUS PNEUMONIAE; STROKE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 43149111819     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. American Stroke Association. Sickle cell disease. Available at www.strokeassociation.org/presenter.jhtml?identifier=3034962. Accessed August 10, 2007.
2. Nietert PJ, Silverstein MD, Abboud MR. Sickle cell anemia: Epidemiology and cost of illness. Pharmacoeconomics 2002;20:357-366.
3. Steiner C, Miller J. Sickle cell disease patients in U.S. hospitals, 2004. Healthcare Cost and Utilization Project (HCUP) Statistical Brief No. 21, December 2006. Rockville, Md: Agency for Healthcare Research and Quality. Available at: www.hcup-us.ahrq.gov/reports/statbriefs/sb21.pdf. Accessed 2/24/2008.
4. Anemia, sickle cell. National Library of Medicine. Available at: www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View.ShowSection&rid=gnd.section. 98. Accessed October 8, 2007.
5. Sickle cell anemia. ACP PIER & AHFS DI Essentials, 2007. American College of Physicians (Philadelphia, Pa.), Physician's Information and Education Resource and American Hospital Formulary Service, Drug Information. Available at: http:/online.statref.com/titles/titleinfopage.aspx?titleid=92. Accessed December 14, 2007.
6. A brief history of sickle cell disease. Harvard University Information Center for Sickle Cell and Thalassemic Disorders. Available at: http://sickle.bwh.harvard.edu/scd_history.html. Accessed December 17, 2007.
7. Fosdal MB, Alexandrov AW. Events of hospitalization among children with sickle cell disease. J Pediatr Nurs 2007;22:342-346.
8. Driscoll CM. Sickle cell disease. Pediatr Rev 2007;28:259-267.
9. Raphael RI, Vichinsky EP. Pathophysiology and treatment of sickle cell disease. Clin Adv Hematol Oncol 2005;3:492-505.
10. Iannone R, Ohene-Frempong K, Fuchs EJ, et al. Bone marrow transplantation for sickle cell anemia: Progress and prospects. Pediatr Blood Cancer 2005;44:436-440.
11. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-769.
12. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-1322.
13. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on morbidity and mortality in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
14. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: A pediatric clinical trial. Blood 1996;88(6):1960-1964.
15. Kinner TR, Helms RW, O'Branski EE, et al., Pediatric Hydroxyurea Group. Safety of hydroxyurea in children with sickle cell anemia: Results of the HUG-KIDS study, a phase I/II trial. Blood 1999;94(5):1550-1554.
16. Zimmerman SA, Schultz WH, Davis JS, et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103(6):2039-2045.
17. Marlowe KF, Chicella MF. Treatment of sickle cell pain. Pharmacotherapy 2002;22(4):484-491.
18. Gonzalez ER, Bahal N, Hansen LA, et al. Intermittent injection vs. patient-controlled analgesia for sickle cell crisis pain: Comparison in patients in the emergency department. Arch Intern Med 1991;151(7):1373-1378.
19. Okomo U, Meremikwu MM. Fluid replacement therapy for acute episodes of pain in people with sickle cell disease (Cochrane Review). In: The Cochrane Library. Issue 2, 2007. Article No. CD005406.
20. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021-1029.
21. Falletta JM, Woods GM, Verter JI, et al. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995;127:685-690.
22. The Management of Sickle Cell Disease, 4th ed. revised, June 2002. National Institutes of Health/National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources, NIH Pub No. 02-2117.
23. Gatson MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: A randomized trial. N Engl J Med 1986;314:1593-1599.
24. What is sickle cell anemia? National Heart, Lung, and Blood Institute (NHLBI). Available at: www.nhlbi.nih.gov/health/dci/Diseases/Sca/SCA_WhatIs. html. Accessed August 10, 2007.
25. Pai VB, Nahata MC. Duration of penicillin prophylaxis in sickle cell anemia: Issues and controversies. Pharmacotherapy 2000;20(1):110-117.
26. Centers for Disease Control and Prevention (DCDC). Sickle cell disease: Five tips to help prevent infection. Available at: www.cdc.gov/ncbddd/ sicklecell/tips_prevent.htm. Accessed October 16, 2007.
27. Adams RJ, McKie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998;339:5-11.
28. The Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-2778.
29. Zimmerman SA, Schultz WH, Burgert S, et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 2007;110:1043-1047.
30. Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136(3):501-508.
31. Lerner NB. Aspirin prophylaxis in sickle cell disease. Trial No. NCT00178464. Available at: http://clinicaltrials.gov/ct/show/NCT00178464?order= 1. Accessed September 5, 2007.
32. Stuart MJ, Nagel RL. Sickle cell disease. Lancet 2004;364(9442):1343-1360.
33. Rabb LM, Grandison Y, Mason K, et al. A trial of folate supplementation in children with homozygous sickle cell disease. Br J Haematol 1983;54:589-594.
34. Rodriguez-Cortez HM, Griener JC, Hyland K, et al. Plasma homocysteine levels and folate status in children with sickle cell anemia. J Pediatr Hematol Oncol 1999;21:219-223.
35. Nelson SC, Adade BB, McDonough EA, et al. High prevalence of pulmonary hypertension in children with sickle cell disease. J Pediatr Hematol Oncol 2007;29:334-337.
36. Castro O, Hoque M, Brown MD. Pulmonary hypertension in sickle cell disease: Cardiac catheterization results and survival. Blood 2003;101:1257-1261.
37. Machado RF, Martyr S, Kato GJ et al. Sildenafil therapy in patients with sickle-cell disease and pulmonary hypertension. Br J Haematol 2005;130:445-453.
38. Adeyoju AB, Olujohunbge ABK, Morris J, et al. Priapism in sickle-cell disease: Incidence, risk factors and complications. An international multicentre study. BJU Int 2002;90(9):898-902.
39. Fowler JE, Koshy M, Strub M, et al. Priapism associated with the sickle cell hemoglobinopathies: Prevalence, natural history and sequelae. J Urol 1991;145(1):65-68.
40. Pryor J, Akkus E, Alter G, et al. Priapism. J Sex Med 2004;1(1):116-120.
41. Iyamu EW, Turner EA, Asakura T. In vitro effects of niprisan (Nix-0699): A naturally occurring, potent antisickling agent. Br J Haematol 2002;118(1):337-343.
42. Wambebe C, Khamofu H, Momoh JA, et al. Double-blind, placebo-controlled, randomized cross-over clinical trial of niprisan in patients with sickle cell disorder. Phytomedicine 2001;8(4):252-261.
43. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343-1360.
44. Christensen D. Nitric oxide may help treat sickle cell anemia. Science News 2000;157(5):78-81.
45. Head CA, Brugnara C, Martinez-Ruiz R, et al. Low concentrations of nitric oxide increase oxygen affinity of sickle erythrocytes in vitro and in vivo. J Clin Invest 1997;100(5):1193-1198.
46. Waugh WH, Daeschner CW, Files BA, et al. Evidence that L-arginine is a key amino acid in sickle cell anemia: A preliminary report. Nutr Res 1999;19(4):501-518.
47. Morris CR, Morris SM, Hagar W, et al. Arginine therapy: A new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003;168:63-69.
48. Williams R, Olivi S, Li CS, et al. Oral glutamine supplementation decreases resting energy expenditure in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol 2004;26(10):619-625.
49. Niihara Y, Zerez CR, Akiyama DS, et al. Increased red cell glutamine availability in sickle cell anemia: Demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J Lab Clin Med 1997;130(1):83-90.
50. Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol 1998;58:117-121.
51. De Franceschi L, Bachir D, Galacteros F, et al. Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest 1997;100(7):1847-1852.